In plain terms

The claim being assessed: Avoiding routine childhood vaccination prevents autism and produces a better overall health outcome in children eligible for routine immunization.

Where the evidence stands: Α — Speculative. An idea with a story behind it, but no evidence yet that it actually happens.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Overall Α follows preregistered primary SC3: avoiding eligible routine vaccination has no verified autism-prevention/net-health benefit in the examined originals. SC1 and SC2 are also Α because the set establishes no credible reproducible positive clinical vaccine-ASD association; restricted toxicity findings are retained without importing their inference into human ASD. Separate SC4 reaches Η through randomized antigen-specific prevention plus independently structured exposure/refusal/outbreak evidence. The harm score does not itself assign the nominal benefit score.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Avoiding routine childhood vaccination has no demonstrated autism-prevention benefit; loss of pathogen-specific protection increases infection risk, while genuine vaccine adverse events require separate assessment.

Implications for health and treatment: Overall Α follows preregistered primary SC3: avoiding eligible routine vaccination has no verified autism-prevention/net-health benefit in the examined originals. SC1 and SC2 are also Α because the set establishes no credible reproducible positive clinical vaccine-ASD association; restricted toxicity findings are retained without importing their inference into human ASD. Separate SC4 reaches Η through randomized antigen-specific prevention plus independently structured exposure/refusal/outbreak evidence. The harm score does not itself assign the nominal benefit score.

Limits for individual care: 62 primary reports with 7 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 62 primary reports; claims: 67; verified: 67; unverified: 0. Verification is bounded attribution. Access: 7 partial-body and 55 bounded abstract/status examinations. Literature cutoff: 2026-10-12; source examination UTC date: 2026-10-12. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 4 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Avoiding routine childhood vaccination has no demonstrated autism-prevention benefit; loss of pathogen-specific protection increases infection risk, while genuine vaccine adverse events require separate assessment.

Deciding experiment: Pre-register a target-trial emulation of existing naturally varying vaccine timing or historical matched formulations without withholding recommended vaccination. Define eligibility and familial risk before outcomes, validate exposure and incident diagnosis, use correct time-at-risk and age landmarks, measure healthcare contact and independent negative controls, and link confirmed infection, serious morbidity and specific adverse events over a stated horizon. Independently replicate absolute net outcomes and proposed dose predictions; no responder-only or postdiagnosis susceptibility scope.

Belief versus evidence: Overall Α follows preregistered primary SC3: avoiding eligible routine vaccination has no verified autism-prevention/net-health benefit in the examined originals. SC1 and SC2 are also Α because the set establishes no credible reproducible positive clinical vaccine-ASD association; restricted toxicity findings are retained without importing their inference into human ASD. Separate SC4 reaches Η through randomized antigen-specific prevention plus independently structured exposure/refusal/outbreak evidence. The harm score does not itself assign the nominal benefit score.

Best-supported rival: Pathogen-specific protection with adverse-event boundaries. The randomized pertussis-component versus DT-only trial (PMID 8538705) establishes clinical pathogen prevention independently of refusal/healthcare-seeking confounding, while the 2026 age-landmark MMR-autism analysis (PMID 42520244) finds a near-null ASD estimate with a separate negative-control exposure. Together they distinguish actual protection from diagnosis-timing coincidence; the negative control tests specified biases rather than proving all confounding absent.

COMPETING MECHANISTIC MODELS

Rank 1: Pathogen-specific protection with adverse-event boundaries (Η). Immunization reduces defined clinical infection risks while formulation, age and contraindications determine specific adverse-event risks. Randomized pertussis/varicella prevention, refusal cohorts, missing-dose gradients and independently observed outbreaks converge on clinical protection and its loss. Protection varies by product/dose/time/exposure and can fail; febrile seizures, ITP and rare anaphylaxis are real boundaries rather than evidence of autism causation.

Rank 2: Developmental liability and diagnostic timing (Β). Familial developmental liability and age-dependent recognition can coincide with vaccination timing without vaccine causation. Affected-sibling risk is high while MMR receipt does not increase ASD; age-landmark, regression-clustering and withdrawal tests narrow timing explanations. This selected vaccine-focused set does not fully explain all autism genetic/environmental causes or every individual developmental trajectory.

Rank 3: Ascertainment and exposure misclassification (Γ). Healthcare contact, early-intervention requirements, calendar trends and reporting alter apparent vaccine-autism associations. Atlanta late-vaccination associations, EHR age anchoring and passive-report versus service-prevalence divergence map specific bias mechanisms. Bias is not a complete explanation for every biological autism trend, and a near-null negative control cannot eliminate all residual confounding.

Rank 4: Autism prevention by vaccine avoidance (Α). Avoiding routine vaccines prevents autism and improves eligible children's overall health. Its strongest case is known dose-dependent mercury toxicity, susceptible-strain animal findings and positive but weak aggregate/referred-case associations. Actual vaccine-exposure clinical studies fail its main predictions, and loss of infection protection contradicts the proposed net-health improvement.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Avoiding routine childhood vaccination prevents autism and produces a better overall health outcome in children eligible for routine immunization.

Primary SC3 is the registered clinical policy/benefit claim. Etiologic mechanisms and separately stated harms are reported at their own scope; proof of harm does not itself assign the nominal benefit level.

Selection: position 20 in this three-case user-selected harm-related batch, registered on 2026-10-12; this is not a measured popularity ranking. Registered claim assessed against original sources. Any carried-forward edition and prior visibility are recorded in the change record; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: No frozen rubric explicitly covers developmental vaccine etiology or net preventive policy. 07 is used as the nearest clinical diagnostic routing for SC1–SC3, with a preregistered adaptation to incident developmental diagnosis, valid dose/formulation natural experiments and outcome-ascertainment controls rather than psychiatric symptom treatment. 05 governs antigen-specific infection prevention with incidence endpoints. Autism is neurodevelopmental, not neurodegenerative. The literal rubric threshold text is retained, while applied criteria below distinguish this adaptation. Subjective-effect/placebo confounders are relevant to rating-based chelation claims but not automatically imposed on registry autism diagnoses or pathogen-confirmed prevention trials.

The two etiologic claims are distinct. Thimerosal is a historical ethylmercury preservative; MMR is a live-virus combination that has never contained it. Cell or rodent mercurial toxicity warrants dose/route/kinetic scrutiny but does not identify MMR as a mercury exposure. Human infant studies estimate faster ethylmercury blood clearance than oral methylmercury; monkey data also show slower brain than blood clearance and a substantial retained inorganic fraction. Rapid blood decline is therefore not proof of instantaneous absence from brain, nor does retention itself prove autism. PMID 12480426; PMID 18245396; PMID 19560158; PMID 16079072.

Strong individual-exposure and formulation evidence challenges the thimerosal autism claim. The Danish same-vaccine formulation cohort finds no increased autism risk or ethylmercury dose trend. Validated in-person ASD case-control work also finds no increased prenatal/infant exposure risk. A randomized infant dose-regimen follow-up reports only small selected neuropsychological differences after many comparisons. Thompson's 42-outcome study explicitly did not assess autism; it must not be credited as a direct ASD-incidence null. Population phaseout trends are useful triangulation, with diagnostic/ascertainment limitations retained. PMID 14519711; PMID 20837594; PMID 19171612; PMID 17898097; PMID 16818529; PMID 18180424.

Contrary findings were examined rather than removed by label. VAERS/education and birth-cohort VSD analyses report associations, but passive-report proportions are not incidence and aggregated calendar exposures are not individually validated dose contrasts. Referred-clinic Rh-negative comparisons use historical controls and indirect exposure. Rodent studies show genuine tested dose/sex/strain toxicity, including strains without the same effects; the primate pilot shows imaging differences, whereas the later schedule experiment is null for tested behavior/pathology. Human autism and vaccine-dose transport remain separate questions. PMID 14534046; PMID 16733480; PMID 18482737; PMID 17674242; PMID 18404135; PMID 15184908; PMID 21549155; PMID 20628439; PMID 26417083.

MMR results converge across several design questions without claiming mathematical zero risk. Danish registry studies, UK matched data and US affected-sibling analyses show no increased ASD risk. The 2026 Cosmos cohort of 2,560,035 children uses age-based landmarks and reports aHR 0.97 with 99% CI 0.91–1.03; pneumococcal booster negative control gives aHR 1.01. This tests specific bias pathways and strengthens triangulation, but does not exclude every residual confounder. Late vaccination by 36 months in Atlanta can reflect special-education enrollment after developmental concern; it is not the same as the null routine 18/24 month comparisons. Withdrawal in Yokohama does not reduce ASD incidence. PMID 12421889; PMID 30831578; PMID 15364187; PMID 25898051; PMID 42520244; PMID 14754936; PMID 15877763.

Mechanistic markers and chelation do not fill the causal gap. Measles antibody differences after diagnosis do not establish vaccine-strain disease, and blood PCR/calprotectin studies fail selected persistence/inflammation predictions. The DMSA study explicitly states that every participant received an initial active screening course and that the later comparison is one versus seven courses; both arms improve within groups, without a significant demonstrated between-arm clinical advantage. Provoked metal excretion uses a reference range for non-chelated children, and adverse dropouts occur. This is neither a never-treated placebo efficacy demonstration nor proof vaccines caused autism. PMID 12849883; PMID 16555271; PMID 12427783; PMID 19852789; PMID 19852790.

The prevention evidence has a different direction and stronger causal content. Randomized pertussis-antigen inclusion versus DT-only control changes confirmed infection; whole-cell/acellular formulations differ in efficacy and reactogenicity. Randomized varicella schedules versus MMR-only control show clinical protection over 10 years, stronger with two doses. Explicit refusal, missing-dose gradients and independent measles outbreaks connect lost protection with real infection and hospitalization. Contacts, importation, community clustering and combined containment actions remain relevant, and not all unvaccinated outbreak cases were vaccination-eligible. PMID 8538705; PMID 9682390; PMID 34435933; PMID 11135778; PMID 19482753; PMID 20048244; PMID 24019039; PMID 24913790; PMID 27705270; PMID 32160662.

Safety boundaries remain visible. Chart-adjudicated anaphylaxis is rare but real, estimated 1.31 per million doses across children/adults in the examined VSD study. MMR has a short-window ITP signal. First-dose MMRV in 12–23 month-olds carries an additional 7–10 day febrile-seizure risk relative to separate MMR plus varicella; the 4–6 year findings differ. These are specific clinical adverse events, not autism evidence or proof routine avoidance improves total health in eligible children. Diagnosed ASD children's later fever/ED responses are a separate safety question from autism etiology. PMID 26452420; PMID 12534647; PMID 20587679; PMID 22473362; PMID 25560438; PMID 35315325.

Consensus helped locate comparisons and timeline leads, but its declared full-text access was to three secondary reviews, not to the original studies checked here. Its wording that a negative control excludes residual confounding is too strong. It misattributes PMID 21058170 to Seneff; the original authors are Gallagher and Goodman and the PubMed record is retracted, linked notice PMID 42166532. That source and the retracted 1998 Wakefield report do not enter the 62 primary-source count or support ledger. Infection claims are linked here to actual original refusal, randomized prevention and outbreak studies rather than mismatched review/Geier citations.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Α follows preregistered primary SC3: avoiding eligible routine vaccination has no verified autism-prevention/net-health benefit in the examined originals. SC1 and SC2 are also Α because the set establishes no credible reproducible positive clinical vaccine-ASD association; restricted toxicity findings are retained without importing their inference into human ASD. Separate SC4 reaches Η through randomized antigen-specific prevention plus independently structured exposure/refusal/outbreak evidence. The harm score does not itself assign the nominal benefit score. Sensitivities: weakest-link Α; primary-subclaim Α; scope-matched Α.

Decisive-perturbation inventory and causal tally

[6] Prespecified age-landmark analyses in 2.56 million US EHR children yield MMR aHR 0.97 and pneumococcal negative-control aHR 1.01. Near-null negative control tests specific shared biases, not every residual confounder; original body not accessed.

[8] Yokohama birth-cohort ASD incidence continues rising after complete MMR withdrawal from 1993. Diagnostic/ascertainment trends can change over time; population withdrawal is stronger against a main cause than against every rare subtype effect.

[14] Same-vaccine Danish formulations with or without thimerosal show no increased ASD and no dose trend in 467 450 children. Formulation/calendar assignment remains observational and shares Danish registry failure modes; confidence bounds do not prove absolute zero risk.

[21] Children randomized in infancy to different thimerosal-dose vaccine regimens have few small neuropsychological differences at 10 years. Follow-up participation about 70%, multiple comparisons and other formulation differences limit mediation; the outcome is not an autism-incidence test.

[44] Colorado exemptions predict substantially higher measles/pertussis risk and higher community incidence/outbreak associations. Nonrandom refusal and social/contact clustering remain; actual community associations are distinguished from modeling and pathogen exposure is required.

[54] Randomized Swedish infant pertussis-component vaccines versus DT-only control reduce confirmed pertussis, with product-specific efficacy and reactogenicity. Controlled antigen prevention is not zero-risk or protection from every pathogen; whole-cell and acellular results differ and linked erratum details unexamined.

[56] Randomized varicella-antigen schedules versus MMR-only control provide confirmed-varicella protection through 10 years, with stronger two-dose benefit. Russian subset is part of one international NCT00226499 trial, not an independent efficacy trial; no single cohort establishes all-vaccine safety.

[59] First-dose MMRV has about twice the 7–10 day febrile-seizure risk compared with separate MMR plus varicella in 12–23 month-olds. Formulation/age-window adverse effect is not autism or a reason to generalize all vaccination avoidance; partially overlapping VSD follow-ups count as shared components.

Tally: 7 positive qualifying study units across scoped subclaims; 51 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Reports sharing participants, models or instruments are not independent causal lines. Pivotal nulls do not earn positive threshold crossings.

Cap audit, precedence and Β/Γ/Δ boundary

Cell toxicology can demonstrate real toxicity without establishing vaccine-dose human autism; those offered inferences remain scoped. Individual formulation/dose contrasts and natural withdrawals are valid etiologic tests under the declared developmental adaptation, but negative results do not grant a positive causal crossing. SC4's randomized infection-incidence prevention is a functional clinical endpoint, not a cytokine biomarker; it is assessed together with independent refusal/exposure/outbreak classes and is not re-capped from its observational leg. Rare vaccine-specific harms are retained and do not imply autism causality or a universal net benefit of avoidance.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Cell/rodent toxicity and imaging/antibody markers do not establish incident human autism at vaccine exposures. Ecological VAERS report proportions, cohort exposure estimates and referred-case historical controls retain association and ascertainment limits. Clinical preventive trials with pathogen-confirmed outcomes are not re-capped as mere biomarkers or pure association. Open-label or within-group chelation ratings cannot cross the treatment/etiology boundary; all participants in the examined DMSA study received initial active drug. MMR and thimerosal-containing historical vaccines are distinct exposures; MMR has never contained thimerosal.

SC1 cap: “Use for claims sustained by phenomenological narrative, metaphor, anecdote, or self-selected user surveys.” The examined set does not establish a reproducible positive human vaccine-ethylmercury/ASD association. Cell and selected rodent experiments demonstrate restricted toxicity, but neither their endpoints nor dose/kinetic transport establish vaccine-dose human autism. Positive ecological, passive-report and referred-case associations fail to reproduce in better individual-dose, matched-formulation and validated diagnostic comparisons. Thus the registered clinical etiologic claim is Α, while real restricted toxicology is retained separately; a Β ceiling is not treated as an earned associational rung.

SC2 cap: “Use for claims sustained by phenomenological narrative, metaphor, anecdote, or self-selected user surveys.” No credible reproducible positive MMR/ASD association is established in the examined original set. Anecdotal timing, postdiagnosis antibodies and a later school-entry association do not survive stronger age, exposure, onset, familial-risk and withdrawal comparisons. The registered etiologic claim is therefore Α. This does not assert that every conceivable rare vaccine adverse event is impossible or that ASD itself is speculative.

SC3 cap: “Use for claims sustained by phenomenological narrative, metaphor, anecdote, or self-selected user surveys.” No examined original clinical study demonstrates that avoiding routine childhood vaccination prevents autism and improves overall health among eligible children. The claim remains narrative/unsupported at Α. Negative autism exposure tests do not earn a positive causal crossing; separate infection-prevention and refusal-outbreak evidence opposes the proposed net benefit. This level was derived from the source comparison rather than assigned because the topic is historically disputed.

SC1 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors

Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. The examined set does not establish a reproducible positive human vaccine-ethylmercury/ASD association. Cell and selected rodent experiments demonstrate restricted toxicity, but neither their endpoints nor dose/kinetic transport establish vaccine-dose human autism. Positive ecological, passive-report and referred-case associations fail to reproduce in better individual-dose, matched-formulation and validated diagnostic comparisons. Thus the registered clinical etiologic claim is Α, while real restricted toxicology is retained separately; a Β ceiling is not treated as an earned associational rung.

SC2 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors

Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. No credible reproducible positive MMR/ASD association is established in the examined original set. Anecdotal timing, postdiagnosis antibodies and a later school-entry association do not survive stronger age, exposure, onset, familial-risk and withdrawal comparisons. The registered etiologic claim is therefore Α. This does not assert that every conceivable rare vaccine adverse event is impossible or that ASD itself is speculative.

SC3 field-valid definition: “at least one of: - Active comparator matched for acute subjective effect, blinding integrity measured and reported - Blinded on/off, staggered-onset, or randomized-withdrawal neuromodulation, reversible and within-subject - Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia - Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker - Psychotherapy component dismantling, or scaffold removal from a drug arm, with blinded assessors

Rating-scale or biomarker change alone does NOT satisfy this threshold when the claim is functional, and statistical mediation alone never satisfies it.” Positive full-scope result: no. No examined original clinical study demonstrates that avoiding routine childhood vaccination prevents autism and improves overall health among eligible children. The claim remains narrative/unsupported at Α. Negative autism exposure tests do not earn a positive causal crossing; separate infection-prevention and refusal-outbreak evidence opposes the proposed net benefit. This level was derived from the source comparison rather than assigned because the topic is historically disputed.

SC4 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: yes. Vaccine avoidance removes demonstrated pathogen-specific protection and increases infection susceptibility where exposure occurs. Randomized pertussis-component versus matched DT-control and varicella-antigen versus MMR-control trials establish clinical prevention; refusal/exemption studies, missing-dose gradients and laboratory-confirmed outbreaks connect loss of protection to individual and community risk. These classes address different failure modes and converge at Η for the specified infection-risk claim. They do not mean every unvaccinated child becomes infected, vaccines prevent every case, or every formulation/recipient has zero adverse-event risk.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Incident ASD is the clinical outcome; the adapted causal criterion is a valid individual dose/formulation contrast or natural experiment with diagnosis/time-at-risk validation, calendar/healthcare-use control, and clinically relevant exposure. Cell toxicity or general mercury hazards are not vaccine-dose ASD causality.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Incident ASD and regression/timing are assessed against MMR exposure with validated baseline eligibility, age/time-at-risk, predefined familial risk and credible ascertainment. A matched natural exposure contrast is eligible without requiring a psychedelics-style active subjective comparator. No vaccine-induced autism-positive crossing is found.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Net child health requires prospectively defined clinical autism, infection and adverse-event outcomes in an eligible population. Target-trial emulation of existing natural exposure variation can be informative; deliberately withholding standard vaccination to test autism is not proposed. One marker, one disease absence or a postdiagnosis rating improvement cannot establish superior overall health.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): 05 explicitly names vaccine trials with incidence endpoints as field-valid equivalents. Randomized pathogen-antigen inclusion versus matched control and clinical infection outcomes test prevention; outbreak/refusal/dose contrasts connect withdrawal or absence of that protection to exposure-conditioned infection risk. This is a preventive-policy mechanism adaptation, not a cytokine-driver claim.

SC1 literal Γ hard rule: “Functional-unblinding rule. Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mediation-by-correlation rule. Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Open-label rule. Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Applies to the uncontrolled or cell-only positive support class, with ceiling Γ; it does not upgrade that class or describe the whole source set.

SC1 literal Γ hard rule: “Unblinded-rater rule. Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Acute-pharmacodynamic rule. Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Rodent-proxy rule. Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Functional-unblinding rule. Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mediation-by-correlation rule. Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Open-label rule. Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Applies to the uncontrolled or cell-only positive support class, with ceiling Γ; it does not upgrade that class or describe the whole source set.

SC2 literal Γ hard rule: “Unblinded-rater rule. Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Acute-pharmacodynamic rule. Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Rodent-proxy rule. Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Functional-unblinding rule. Inert-placebo trial of an intervention with unmistakable acute subjective effects — psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT — with no blinding-integrity check reported. Such a trial did not control what it claims to control.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mediation-by-correlation rule. Candidate mediator correlated with outcome, never manipulated.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Open-label rule. Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.” Applies to the uncontrolled or cell-only positive support class, with ceiling Γ; it does not upgrade that class or describe the whole source set.

SC3 literal Γ hard rule: “Unblinded-rater rule. Outcomes rated by clinicians who delivered the intervention or knew allocation.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Acute-pharmacodynamic rule. Acute molecular, occupancy, or imaging change with no link to symptom trajectory.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Rodent-proxy rule. Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Ex vivo functional assays alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Cytokine profile plus in vitro mechanistic work, no in vivo necessity” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Broad immunosuppression effect with pleiotropy” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Correlational human data plus in vitro mechanism” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

Upward threshold ladder

SC1 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. A clinically relevant dose/formulation effect on independently validated incident ASD must survive calendar/healthcare-use and diagnostic-latency control, dose prediction, replication and selective exposure comparisons. It cannot be rescued by defining susceptible responders after diagnosis.

SC2 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. A prespecified MMR effect on incident ASD or regression must reproduce under valid age/time-at-risk, ascertainment and baseline familial-risk controls, with exposure-before-outcome evidence and independent validation.

SC3 Δ: “Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.” Satisfied: no. Pre-register target-trial emulation of existing natural vaccination/formulation variation, validate timing and diagnosis, measure linked infection and adverse-event outcomes, and compare absolute net health over specified horizons. No trial deliberately withholding standard childhood immunization is proposed.

SC4 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: yes.

SC4 Ε: “Requires context-specific causality with explicit scope restriction.” Satisfied: yes.

SC4 Ζ: “Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.” Satisfied: yes.

SC4 Η: “Requires robust upstream causal evidence across systems and interventions.” Satisfied: yes.

SC4 Θ: “Requires predictive consistency and minimal contradiction in the claimed disease scope.” Satisfied: no. For Θ, predict absolute individual/community risk prospectively across independently defined vaccines, exposure networks, ages and horizons with minimal unresolved exceptions. For Ω, establish necessity and sufficiency of the claimed immune mechanism within scope; prevention is not absolute infection immunity.

Upper ladder: Same-vaccine formulation changes, naturally discontinued exposures, randomized infant dose assignments, age-landmark/negative-control studies and large validated clinical cohorts were considered for the autism/benefit subclaims. None supplies a positive clinical autism-prevention crossing. SC4's randomized antigen-specific prevention and independently structured exposure/refusal evidence can reach higher rungs under 05; absence of an unethical all-vaccine-withholding RCT is not imposed as a universal ceiling.

Independence: The 256 ASD cases/752 controls in thimerosal PMID 20837594 and antigen PMID 23545349 are one parent study. Thompson PMID 17898097 and latent-factor PMID 21785120 reuse 1047 children. UK case-series PMID 10376617 and PMID 11395196 are one series. DMSA Part A/Part B share one trial. Danish registry cohorts/formulation analyses may overlap or share diagnostic systems; VSD safety reports overlap sites/years and some recipients. Colorado pertussis/varicella share a health-plan framework. International varicella NCT00226499 Russian 10 year subset and Italian pertussis follow-up count as parent trials, not extra trials. 62 reports are not 62 independent causal lines. The positive infection-risk inference rests on two broad error-mode classes, randomized antigen prevention and naturally occurring exposure/loss of protection. Autism-negative and adverse-event studies audit distinct claims but are not counted as extra positive infection causal lines.

Randomized antigen-specific clinical prevention [54, 55, 56]: Random allocation and matched vaccinated controls address refusal, healthcare use and baseline contact confounding for pathogen-specific clinical endpoints; trial ascertainment/blinding and product/time limits are retained.

Loss of protection under naturally occurring exposure [44, 46, 47, 48, 49, 50, 51]: Chart-validated refusal, missing-dose gradients and laboratory-confirmed imported outbreaks test loss of protection in actual communities with different allocation/ascertainment structures from trials. Cohorts and outbreaks share possible contact-network confounding and count as one broad natural-exposure class, not independent lines merely because there are multiple papers.

Falsification and pitfalls

Predicted dose/formulation and withdrawal signatures fail in stronger clinical exposure tests. Same-vaccine ethylmercury dose/formulation, MMR temporal/familial-risk tests and withdrawal do not reproduce the main autism prediction. These contradict the nominal positive association; null designs do not earn a positive causal crossing. Additional downgrade: False.

Net-health improvement claim conflicts with demonstrated loss of pathogen protection. Randomized pathogen-specific prevention plus refusal/outbreak clinical consequences oppose the proposed routine-avoidance benefit. SC3 is already Α from lack of positive clinical support; no below-ladder downgrade is possible. Additional downgrade: False.

Ethylmercury, methylmercury and MMR conflated. Compound, formulation, route and dose are different and must be observed.

Passive reports or service counts become incidence. VAERS and DDS measure reporting/active clients with calendar and latency effects.

Negative control eliminates every bias. Its interpretation depends on shared confounding pathways and exposure measurement.

General toxicity or biomarker becomes clinical autism. Cell ROS, monkey imaging, rodent behavior and human tics are distinct outcomes.

Within-group chelation improvement becomes placebo efficacy. Both DMSA arms received initial active treatment, and post-dose enrichment changes the sample.

All-vaccine zero-risk rhetoric. Specific anaphylaxis, ITP and age/formulation seizure signals are retained.

Adversarial steelman: above, then below

One rung above the overall answer, Β: positive passive-report/cohort aggregate associations, susceptible-strain neurotoxicity, rare real vaccine adverse effects and vulnerable developmental timing make safety scrutiny reasonable. Yet the registered clinical avoidance-benefit claim lacks a credible reproducible positive association: reporting proportions, referred historical controls and postdiagnosis markers do not demonstrate autism prevention or net health improvement. Restricted toxicity is real evidence for a different system/scope rather than positive credit for this clinical proposition.

Α is the lowest HSEF rung, so no lower letter exists. A stronger dismissal would claim absolute zero biological risk or no value in further safety surveillance; that is rejected because recognized specific adverse events and finite precision are documented. The low nominal benefit score must coexist with positive infection-prevention causality and honest safety boundaries.

Retain overall Α for the unsupported avoidance-benefit claim, without converting that into an all-vaccine-zero-risk assertion. Report Η for the separately stated infection-risk consequence and preserve the strongest toxicity/positive-association evidence within its actual system and limitations.

Final score, causal direction and M/S/D

Overall Α follows preregistered primary SC3: avoiding eligible routine vaccination has no verified autism-prevention/net-health benefit in the examined originals. SC1 and SC2 are also Α because the set establishes no credible reproducible positive clinical vaccine-ASD association; restricted toxicity findings are retained without importing their inference into human ASD. Separate SC4 reaches Η through randomized antigen-specific prevention plus independently structured exposure/refusal/outbreak evidence. The harm score does not itself assign the nominal benefit score.

For the nominal vaccine-to-autism-to-beneficial-avoidance mechanism, no demonstrated clinical causal dependency in either direction is established; temporal coincidence and weak associations do not supply it. Step 2 therefore gives epiphenomenon for this nominal relationship, not for autism itself or vaccination generally. The separate SC4 consequence is causally supported: avoiding immunization removes a protective susceptibility barrier while pathogen exposure initiates infection. It does not imply avoidance alone is necessary or sufficient for infection or that vaccines are merely epiphenomenal.

Momentum: Associational only. The 2026 Cosmos age-landmark/negative-control study (PMID 42520244) supplies refined observational safety output. Historical dose/formulation and animal experiments are examined, but no verified new positive native clinical avoidance-for-autism benefit experiment is underway in this bounded set. Ongoing vaccine safety and infection prevention are separate active programs.

Stability: Stable. No verified named pending result was identified that would establish the nominal avoidance-benefit claim. A replicated baseline-defined exposure effect with validated diagnosis and absolute net clinical outcomes could change it; additional safety surveillance can refine vaccine-specific risks without establishing autism causality.

Divergence: Contested. No manufactured field consensus or arithmetic gap. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Pre-register a target-trial emulation of existing naturally varying vaccine timing or historical matched formulations without withholding recommended vaccination. Define eligibility and familial risk before outcomes, validate exposure and incident diagnosis, use correct time-at-risk and age landmarks, measure healthcare contact and independent negative controls, and link confirmed infection, serious morbidity and specific adverse events over a stated horizon. Independently replicate absolute net outcomes and proposed dose predictions; no responder-only or postdiagnosis susceptibility scope.

Readout: Validated incident ASD and absolute pathogen-specific morbidity/serious adverse-event outcomes in an eligible population over prespecified follow-up. Controls: Matched formulation/age/exposure opportunity, time-varying confounding, healthcare-use and diagnostic-latency validation, familial risk, calendar/cohort changes, independent outcome ascertainment, genuine contraindications defined before outcomes. Supporting: An independently replicated dose/formulation effect predicts incident ASD before concerns arise, and avoidance's absolute benefits exceed the lost infection protection and measured harms within a prespecified eligible context. Falsifying: Adequate clinical exposure contrasts remain null for ASD or inferred associations track contact/reporting/calendar rather than dose; avoidance produces infection harm without replicated autism prevention.

KNOWLEDGE GAPS

Historical ethylmercury, environmental methylmercury and MMR are different exposures; actual formulation/dose/route must be recorded.

A near-null negative control limits specified bias pathways but cannot eliminate all residual confounding.

Risk of very rare baseline-defined effects is bounded by precision; no responder-defined subgroup can rescue a failed broad prediction.

General neuropsychological tests, tics, biomarkers and animal proxies are not incident clinical autism.

Absolute net-health outcomes require linked infection, adverse-event and diagnostic follow-up rather than one favorable marker or passive-report trend.

Shared registry/VSD/clinic/trial reports require study grouping and distinct error-mode assessment.

Safety surveillance should preserve known formulation/age-specific adverse events and baseline clinical contraindications.

REVIEWER NOTES

Coordinating source/claim checks and registered-scope adjudication are recorded in COORDINATOR_ADJUDICATION.json. This is not an independent blinded regrade. HSEF letters measure support for the exact positive claim; negative clinical findings and documented harms are explained separately. Divergence is not a probability or a claim of evenly balanced medical evidence.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Original abstract verifies 467450 children, about 2.99 million person-years, autism RR 0.85 (CI 0.60–1.20) and dose slope per 25 micrograms 0.98 (CI 0.90–1.06). Provider's numerical outline agrees, but absence of an observed effect is finite-precision evidence, not a proof that every rare event is impossible. Our access was original abstract/status, not complete full text. Original PMID 14519711.

Original abstract verifies 657 461 children, adjusted HR 0.93 (CI 0.85–1.02), no consistent increased risk in specified familial-risk/timing groups, and explicitly no individual chart review. Provider numbers agree; 'no subgroup vulnerability' must remain limited to tested definitions and their precision. Original access was abstract/status. Original PMID 30831578.

Original abstract verifies 2,560,035 children, MMR aHR 0.97(99% CI 0.91–1.03) and pneumococcal negative-control aHR 1.01(0.99–1.04). Provider's claim that this excludes residual confounding is rejected: it tests specified shared bias pathways and cannot exclude all unmeasured/measurement confounding. Original access was abstract/status; no body audit was claimed. Original PMID 42520244.

Original abstract verifies Colorado exemption-associated measles RR 22.2 and pertussis RR 5.9, plus community incidence/contact findings. Provider attached broad infection-protection claims to secondary reviews and unrelated Geier references rather than this requested original. The review uses the actual original and distinguishes nonrandom refusal/contact clustering from randomized efficacy. Original access was abstract/status. Original PMID 11135778.

Original abstract verifies randomized pertussis components versus DT-only control, product-specific clinical efficacy and higher whole-cell reactogenicity. This supplies actual intervention causality for the infection-risk branch and prevents a universal zero-adverse-effect framing. Original access was abstract/status, with linked erratum details unexamined. Original PMID 8538705.

Original abstract verifies randomized varicella-antigen schedules versus MMR-only control, ten-year confirmed-varicella protection and stronger two-dose efficacy. The Russian sample is a subset of one international NCT00226499 trial, not an extra independent trial. Original access was abstract/status. Original PMID 34435933.

Original Results 5–8 verify faster blood clearance after thimerosal than methylmercury but slower brain than blood clearance and retained inorganic mercury. Provider's shorter-half-life summary is incomplete if taken to mean no brain retention. These kinetic findings do not establish clinical autism; our access includes selected original body passages. Original PMID 16079072.

Original Methods 0/1/7 show late-preterm infants at 32–37 weeks, vaccine exposure, one pre/post sample per infant and population-based half-life modeling. The abstract's 6.3 dayestimate is not repeated individual serial kinetics, evidence for very-preterm infants, or an autism-incidence endpoint. Our access includes selected original Methods. Original PMID 19560158.

Original Methods 1/3–5 and Results 14/20/26/28/30 show that every participant received initial active DMSA, with one-versus-seven-round randomization and no significant reported between-group symptom advantage. Both within-group changes and post-dose metal regressions cannot prove placebo-controlled efficacy or vaccine-caused autism. Part A (PMID 19852789) is the same trial, not an independent primary study; our access includes selected original body. Original PMID 19852790.

Original Methods 3/4/6 verify chart review, medical-officer Brighton adjudication and a per-dose denominator. The abstract reports 33 cases/25,173,965 doses, or 1.31 per million doses, across children/adults. Provider's general rare-adverse-event statement is strengthened with actual original evidence, while autism remains a separate outcome. Our access includes selected original Methods. Original PMID 26452420.

Original abstract verifies first-dose MMRV versus separate MMR plus varicella seizure RR 1.98 and about one excess febrile seizure per 2300 doses in 12–23 month-olds. The older 4–6 year study (PMID 22473362) differs. This is an acknowledged safety boundary, not evidence for autism or a blanket avoidance policy. Original access was abstract/status. Original PMID 20587679.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Vaccine–Autism Claims and Vaccine Avoidance

Selected publication milestones, not an exhaustive history or discovery priority claim.

1996 — randomized pertussis-antigen prevention establishes clinical protection while comparing formulation-specific reactogenicity. Original PMID 8538705.

1999 — UK MMR introduction/onset-clustering tests do not reproduce a major autism timing effect. Original PMID 10376617.

2000 — individual/community exemption analysis links lost vaccine protection to measles/pertussis risk. Original PMID 11135778.

2003 — matched Danish vaccine-formulation/dose comparison finds no increased autism risk from thimerosal; other developmental endpoints remain distinct. Original PMID 14519711.

2005 — Yokohama ASD incidence does not fall after MMR withdrawal, with calendar/diagnostic context retained. Original PMID 15877763.

2009 — neuropsychological follow-up after randomized infant dose-regimen assignment shows few small differences and does not directly test ASD incidence. Original PMID 19171612.

2010 — validated individual thimerosal exposure/ASD comparison is null; later antigen-load analysis (PMID 23545349) reuses the same parent sample. Original PMID 20837594.

2010 — first-dose MMRV febrile-seizure risk is quantified against separate MMR plus varicella, demonstrating measurable formulation-specific safety effects. Original PMID 20587679.

2015 — MMR familial-risk cohort shows no increased ASD association in children with affected older siblings. Original PMID 25898051.

2019 — larger Danish MMR cohort examines defined risk and postvaccination timing groups with no consistent increased ASD signal. Original PMID 30831578.

2022 — ten-year varicella trial follow-up retains pathogen-specific clinical prevention, with dose and parent-trial scope. Original PMID 34435933.

2026 — US EHR age-landmark and negative-control study adds 2.56 million-child near-null MMR/ASD evidence without eliminating every possible residual bias. Original PMID 42520244.

Research gaps

Historical ethylmercury, environmental methylmercury and MMR are different exposures; actual formulation/dose/route must be recorded.

A near-null negative control limits specified bias pathways but cannot eliminate all residual confounding.

Risk of very rare baseline-defined effects is bounded by precision; no responder-defined subgroup can rescue a failed broad prediction.

General neuropsychological tests, tics, biomarkers and animal proxies are not incident clinical autism.

Absolute net-health outcomes require linked infection, adverse-event and diagnostic follow-up rather than one favorable marker or passive-report trend.

Shared registry/VSD/clinic/trial reports require study grouping and distinct error-mode assessment.

Safety surveillance should preserve known formulation/age-specific adverse events and baseline clinical contraindications.

Boundary experiment

Pre-register a target-trial emulation of existing naturally varying vaccine timing or historical matched formulations without withholding recommended vaccination. Define eligibility and familial risk before outcomes, validate exposure and incident diagnosis, use correct time-at-risk and age landmarks, measure healthcare contact and independent negative controls, and link confirmed infection, serious morbidity and specific adverse events over a stated horizon. Independently replicate absolute net outcomes and proposed dose predictions; no responder-only or postdiagnosis susceptibility scope.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 62 REFERENCES PMIDs verified against PubMed metadata (62/62 resolve to the stated first author, year, journal and title; 0 failures, 0 substitutions). The four non-reference identifiers in the text were also verified: PMID 21058170 (Gallagher CM et al., J Toxicol Environ Health A 2010) carries the PubMed "Retracted Publication" type with retraction notice PMID 42166532, exactly as the review states; PMID 26621718 and PMID 26757477 are the Gadad 2015 and Jain 2015 errata. 16 load-bearing numeric claims were spot-checked against the original abstracts, including the Hviid 2003 thimerosal cohort (467 450 children; autism RR 0.85, 95% CI 0.60–1.20; per-25 µg RR 0.98, 0.90–1.06), the Hviid 2019 MMR cohort (657 461 children; adjusted HR 0.93, 0.85–1.02), the 2026 Cosmos EHR cohort (2 560 035 children; MMR aHR 0.97, 99% CI 0.91–1.03; pneumococcal negative-control aHR 1.01, 0.99–1.04), Feikin 2000 (measles RR 22.2, 15.9–31.1; pertussis RR 5.9, 4.2–8.2), McNeil 2016 (33 confirmed anaphylaxis cases after 25 173 965 doses; 1.31 per million), Klein 2010 (days 7–10 RR 1.98; one extra febrile seizure per 2300 doses) and Namazova-Baranova 2022 (NCT00226499 ten-year Russian cohort; two-dose VE 92.4%, one-dose 74.7%). All matched. Scoring logic was re-derived against references/hsef-framework.md and SKILL.md Steps 2–3: hard caps, the pre-registered primary-subclaim aggregation, the three reported sensitivities, the Ζ-and-above independence basis for SC4, and the Momentum/Stability/Divergence artifacts.

Rejected findings (checked, no change). 1. Headline level Α. Argued for Β on the ground that positive passive-report and ecological associations exist. Rejected: cap 2 is a ceiling, not an earned rung, and the review's own SC1/SC2 rationales correctly decline to credit a ceiling as a crossing. Α is the correct letter for a claim with no reproducible positive support, and the review states the contradiction explicitly in Falsification rather than leaving it as mere absence of evidence. 2. SC4 at Η. Checked the independence basis against the v5.2 shared-failure test. Randomized antigen-inclusion trials and naturally occurring refusal/outbreak exposure fail for different reasons (allocation and trial ascertainment versus contact-network and refusal confounding), which the framework lists as typically independent. Θ is correctly withheld for lack of prospective absolute-risk prediction across exposure networks. No change. 3. Aggregation. Primary-subclaim was pre-registered; weakest-link also returns Α (lowest subclaim is Α) and scope-matched also returns Α, because SC4 states the converse consequence rather than the central benefit claim and so is not the scope-matching subclaim. Arithmetic and derivation wording both correct. 4. "Best-supported rival." Verified against the scorecard: models_evaluated[0] is M3 with rank_in_tournament: 1 and is_nominal: false, so the prose names the rank-1 rival and not the nominal. The known renderer defect does not fire here. 5. Momentum boilerplate. "Associational only" is not the boilerplate value at issue and carries a named artifact (the 2026 Cosmos age-landmark study). 6. Collective authors. No dropped-consortium defect: PubMed CollectiveName entries (ALSPAC Study Team, Vaccine Safety Datalink Team, OKAH-182 Russia Study Group) are either rendered or legitimately absorbed into "et al."; no reference begins with a stray comma. 7. Rubric routing. Rubric 07's psychiatry-specific hard rules are quoted verbatim and marked "not triggered literally", with the adaptation declared separately. Awkward but compliant with the cap-precedence obligation to never resolve a collision silently. 8. Retracted and unused sources. The review's exclusion of PMID 21058170 and the 1998 Wakefield report from sources_total is correct under the ledger rule that a source carrying no claim is removed and that corrections do not get their own row.

Residual limitations. Access remains abstract/status for 55 of 62 records, so numeric claims were confirmed against abstracts rather than full reports; the review states this and does not claim otherwise. The four errata without PubMed identifiers remain unexamined in substance. provenance_header.generated_by reads "Codex; HSEF v5.3" rather than naming Sol 6.1; this is a package-wide field and was left for the lead.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Hviid A, Hansen JV, Frisch M et al. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Annals of internal medicine. 2019. PMID 30831578. DOI: 10.7326/M18-2101. Access: abstract_metadata. Study: PMID30831578.

2. Madsen KM, Hviid A, Vestergaard M et al. A population-based study of measles, mumps, and rubella vaccination and autism. The New England journal of medicine. 2002. PMID 12421889. DOI: 10.1056/NEJMoa021134. Access: abstract_metadata. Study: PMID12421889.

3. Taylor B, Miller E, Farrington CP et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet (London, England). 1999. PMID 10376617. DOI: 10.1016/s0140-6736(99)01239-8. Access: abstract_metadata. Study: UK_TAYLOR_AUTISM_SERIES.

4. Jain A, Marshall J, Buikema A et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. 2015. PMID 25898051. DOI: 10.1001/jama.2015.3077. Access: abstract_metadata. Study: PMID25898051.

5. DeStefano F, Bhasin TK, Thompson WW et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan atlanta. Pediatrics. 2004. PMID 14754936. DOI: 10.1542/peds.113.2.259. Access: abstract_metadata. Study: PMID14754936.

6. Burstain TL, Jacques D, Burstain JM. Association Between First MMR Vaccination Before Age 2 Years and Childhood Autism in a U.S. EHR Cohort of 2.5 Million Children. The Pediatric infectious disease journal. 2026. PMID 42520244. DOI: 10.1097/INF.0000000000005349. Access: abstract_metadata. Study: PMID42520244.

7. Smeeth L, Cook C, Fombonne E et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet (London, England). 2004 Sep 11-17. PMID 15364187. DOI: 10.1016/S0140-6736(04)17020-7. Access: abstract_metadata. Study: PMID15364187.

8. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of child psychology and psychiatry, and allied disciplines. 2005. PMID 15877763. DOI: 10.1111/j.1469-7610.2005.01425.x. Access: abstract_metadata. Study: PMID15877763.

9. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine. 2001. PMID 11395196. DOI: 10.1016/s0264-410x(01)00097-4. Access: abstract_metadata. Study: UK_TAYLOR_AUTISM_SERIES.

10. Afzal MA, Ozoemena LC, O'Hare A et al. Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. Journal of medical virology. 2006. PMID 16555271. DOI: 10.1002/jmv.20585. Access: abstract_metadata. Study: PMID16555271.

11. Thjodleifsson B, Davídsdóttir K, Agnarsson U et al. Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine. Gut. 2002. PMID 12427783. DOI: 10.1136/gut.51.6.816. Access: abstract_metadata. Study: PMID12427783.

12. Singh VK, Jensen RL. Elevated levels of measles antibodies in children with autism. Pediatric neurology. 2003. PMID 12849883. DOI: 10.1016/s0887-8994(02)00627-6. Access: abstract_metadata. Study: PMID12849883.

13. Goin-Kochel RP, Mire SS, Dempsey AG et al. Parental report of vaccine receipt in children with autism spectrum disorder: Do rates differ by pattern of ASD onset? Vaccine. 2016. PMID 26868082. DOI: 10.1016/j.vaccine.2016.02.008. Access: abstract_metadata. Study: PMID26868082.

14. Hviid A, Stellfeld M, Wohlfahrt J et al. Association between thimerosal-containing vaccine and autism. JAMA. 2003. PMID 14519711. DOI: 10.1001/jama.290.13.1763. Access: abstract_metadata. Study: PMID14519711.

15. Price CS, Thompson WW, Goodson B et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010. PMID 20837594. DOI: 10.1542/peds.2010-0309. Access: abstract_metadata. Study: VSD_ASD256_CONTROL752.

16. Andrews N, Miller E, Grant A et al. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004. PMID 15342825. DOI: 10.1542/peds.2003-1177-L. Access: abstract_metadata. Study: PMID15342825.

17. Heron J, Golding J, ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004. PMID 15342824. DOI: 10.1542/peds.2003-1176-L. Access: abstract_metadata. Study: PMID15342824.

18. Fombonne E, Zakarian R, Bennett A et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006. PMID 16818529. DOI: 10.1542/peds.2005-2993. Access: abstract_metadata. Study: PMID16818529.

19. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Archives of general psychiatry. 2008. PMID 18180424. DOI: 10.1001/archgenpsychiatry.2007.1. Access: abstract_metadata. Study: PMID18180424.

20. Thompson WW, Price C, Goodson B et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. The New England journal of medicine. 2007. PMID 17898097. DOI: 10.1056/NEJMoa071434. Access: abstract_metadata. Study: THOMPSON_NEUROPSYCH1047.

21. Tozzi AE, Bisiacchi P, Tarantino V et al. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines. Pediatrics. 2009. PMID 19171612. DOI: 10.1542/peds.2008-0795. Access: abstract_metadata. Study: PMID19171612.

22. Verstraeten T, Davis RL, DeStefano F et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003. PMID 14595043. No DOI in PubMed record. Access: abstract_metadata. Study: PMID14595043.

23. Barile JP, Kuperminc GP, Weintraub ES et al. Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later. Journal of pediatric psychology. 2012. PMID 21785120. DOI: 10.1093/jpepsy/jsr048. Access: abstract_metadata. Study: THOMPSON_NEUROPSYCH1047.

24. Young HA, Geier DA, Geier MR. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. Journal of the neurological sciences. 2008. PMID 18482737. DOI: 10.1016/j.jns.2008.04.002. Access: abstract_metadata. Study: PMID18482737.

25. Geier DA, Geier MR. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines. Medical science monitor : international medical journal of experimental and clinical research. 2006. PMID 16733480. No DOI in PubMed record. Access: abstract_metadata. Study: PMID16733480.

26. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatric rehabilitation. 2003. PMID 14534046. DOI: 10.1080/1363849031000139315. Access: abstract_metadata. Study: PMID14534046.

27. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. International journal of toxicology. 2003. PMID 12933322. DOI: 10.1080/10915810305120. Access: abstract_metadata. Study: PMID12933322.

28. Geier DA, Geier MR. A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2007. PMID 17674242. DOI: 10.1080/14767050701228057. Access: abstract_metadata. Study: PMID17674242.

29. Geier DA, Mumper E, Gladfelter B et al. Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment. Neuro endocrinology letters. 2008. PMID 18404135. No DOI in PubMed record. Access: abstract_metadata. Study: PMID18404135.

30. Pichichero ME, Cernichiari E, Lopreiato J et al. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet (London, England). 2002. PMID 12480426. DOI: 10.1016/S0140-6736(02)11682-5. Access: abstract_metadata. Study: PMID12480426.

31. Pichichero ME, Gentile A, Giglio N et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics. 2008. PMID 18245396. DOI: 10.1542/peds.2006-3363. Access: abstract_metadata. Study: PMID18245396.

32. Pichichero ME, Gentile A, Giglio N et al. Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. The Journal of pediatrics. 2009. PMID 19560158. DOI: 10.1016/j.jpeds.2009.04.011. Access: full_text_partial. Study: PMID19560158.

33. Burbacher TM, Shen DD, Liberato N et al. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environmental health perspectives. 2005. PMID 16079072. DOI: 10.1289/ehp.7712. Access: full_text_partial. Study: PMID16079072.

34. Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Molecular psychiatry. 2004. PMID 15184908. DOI: 10.1038/sj.mp.4001529. Access: abstract_metadata. Study: PMID15184908.

35. Olczak M, Duszczyk M, Mierzejewski P et al. Lasting neuropathological changes in rat brain after intermittent neonatal administration of thimerosal. Folia neuropathologica. 2010. PMID 21225508. No DOI in PubMed record. Access: abstract_metadata. Study: PMID21225508.

36. Olczak M, Duszczyk M, Mierzejewski P et al. Persistent behavioral impairments and alterations of brain dopamine system after early postnatal administration of thimerosal in rats. Behavioural brain research. 2011. PMID 21549155. DOI: 10.1016/j.bbr.2011.04.026. Access: abstract_metadata. Study: PMID21549155.

37. Chen YN, Wang J, Zhang J et al. Effect of thimerosal on the neurodevelopment of premature rats. World journal of pediatrics : WJP. 2013. PMID 24235069. DOI: 10.1007/s12519-013-0443-z. Access: abstract_metadata. Study: PMID24235069.

38. Sharpe MA, Livingston AD, Baskin DS. Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA. Journal of toxicology. 2012. PMID 22811707. DOI: 10.1155/2012/373678. Access: full_text_partial. Study: PMID22811707.

39. Gadad BS, Li W, Yazdani U et al. Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology. Proceedings of the National Academy of Sciences of the United States of America. 2015. PMID 26417083. DOI: 10.1073/pnas.1500968112. Access: abstract_metadata. Study: PMID26417083.

40. Hewitson L, Lopresti BJ, Stott C et al. Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: A pilot study. Acta neurobiologiae experimentalis. 2010. PMID 20628439. DOI: 10.55782/ane-2010-1787. Access: abstract_metadata. Study: PMID20628439.

41. DeStefano F, Price CS, Weintraub ES. Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism. The Journal of pediatrics. 2013. PMID 23545349. DOI: 10.1016/j.jpeds.2013.02.001. Access: abstract_metadata. Study: VSD_ASD256_CONTROL752.

42. Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results. BMC clinical pharmacology. 2009. PMID 19852789. DOI: 10.1186/1472-6904-9-16. Access: full_text_partial. Study: ADAMS_DMSA_PARENT.

43. Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC clinical pharmacology. 2009. PMID 19852790. DOI: 10.1186/1472-6904-9-17. Access: full_text_partial. Study: ADAMS_DMSA_PARENT.

44. Feikin DR, Lezotte DC, Hamman RF et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA. 2000. PMID 11135778. DOI: 10.1001/jama.284.24.3145. Access: abstract_metadata. Study: PMID11135778.

45. Salmon DA, Haber M, Gangarosa EJ et al. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA. 1999. PMID 10404911. DOI: 10.1001/jama.282.1.47. Access: abstract_metadata. Study: PMID10404911.

46. Glanz JM, McClure DL, Magid DJ et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics. 2009. PMID 19482753. DOI: 10.1542/peds.2008-2150. Access: abstract_metadata. Study: PMID19482753.

47. Glanz JM, McClure DL, Magid DJ et al. Parental refusal of varicella vaccination and the associated risk of varicella infection in children. Archives of pediatrics & adolescent medicine. 2010. PMID 20048244. DOI: 10.1001/archpediatrics.2009.244. Access: abstract_metadata. Study: PMID20048244.

48. Glanz JM, Narwaney KJ, Newcomer SR et al. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. JAMA pediatrics. 2013. PMID 24019039. DOI: 10.1001/jamapediatrics.2013.2353. Access: abstract_metadata. Study: PMID24019039.

49. Gahr P, DeVries AS, Wallace G et al. An outbreak of measles in an undervaccinated community. Pediatrics. 2014. PMID 24913790. DOI: 10.1542/peds.2013-4260. Access: full_text_partial. Study: PMID24913790.

50. Gastañaduy PA, Budd J, Fisher N et al. A Measles Outbreak in an Underimmunized Amish Community in Ohio. The New England journal of medicine. 2016. PMID 27705270. DOI: 10.1056/NEJMoa1602295. Access: abstract_metadata. Study: PMID27705270.

51. Zucker JR, Rosen JB, Iwamoto M et al. Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019. The New England journal of medicine. 2020. PMID 32160662. DOI: 10.1056/NEJMoa1912514. Access: abstract_metadata. Study: PMID32160662.

52. Hall V, Banerjee E, Kenyon C et al. Measles Outbreak - Minnesota April-May 2017. MMWR. Morbidity and mortality weekly report. 2017. PMID 28704350. DOI: 10.15585/mmwr.mm6627a1. Access: abstract_metadata. Study: PMID28704350.

53. Rosen JB, Arciuolo RJ, Khawja AM et al. Public Health Consequences of a 2013 Measles Outbreak in New York City. JAMA pediatrics. 2018. PMID 30073293. DOI: 10.1001/jamapediatrics.2018.1024. Access: abstract_metadata. Study: PMID30073293.

54. Gustafsson L, Hallander HO, Olin P et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. The New England journal of medicine. 1996. PMID 8538705. DOI: 10.1056/NEJM199602083340602. Access: abstract_metadata. Study: PMID8538705.

55. Salmaso S, Mastrantonio P, Wassilak SG et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group. Vaccine. 1998. PMID 9682390. DOI: 10.1016/s0264-410x(98)00040-1. Access: abstract_metadata. Study: ITALIAN_PERTUSSIS_EFFICACY_PARENT.

56. Namazova-Baranova L, Habib MA, Povey M et al. A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children. Human vaccines & immunotherapeutics. 2022. PMID 34435933. DOI: 10.1080/21645515.2021.1959148. Access: abstract_metadata. Study: VARICELLA_NCT00226499_PARENT.

57. McNeil MM, Weintraub ES, Duffy J et al. Risk of anaphylaxis after vaccination in children and adults. The Journal of allergy and clinical immunology. 2016. PMID 26452420. DOI: 10.1016/j.jaci.2015.07.048. Access: full_text_partial. Study: PMID26452420.

58. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. British journal of clinical pharmacology. 2003. PMID 12534647. DOI: 10.1046/j.1365-2125.2003.01790.x. Access: abstract_metadata. Study: PMID12534647.

59. Klein NP, Fireman B, Yih WK et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010. PMID 20587679. DOI: 10.1542/peds.2010-0665. Access: abstract_metadata. Study: PMID20587679.

60. Klein NP, Lewis E, Baxter R et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012. PMID 22473362. DOI: 10.1542/peds.2011-3198. Access: abstract_metadata. Study: PMID22473362.

61. Klein NP, Lewis E, Fireman B et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015. PMID 25560438. DOI: 10.1542/peds.2014-1822. Access: abstract_metadata. Study: PMID25560438.

62. Zerbo O, Modaressi S, Goddard K et al. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022. PMID 35315325. DOI: 10.1016/j.vaccine.2022.03.031. Access: abstract_metadata. Study: PMID35315325.

Source-specific evidence cards

[1] Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study.

Shows: Danish cohort of 657461 children finds adjusted MMR-autism HR 0.93 with no consistent increase in prespecified sibling-risk, risk-score or timing groups.

Does not show: Registry diagnoses without individual chart review and observational allocation cannot exclude every exceptionally rare effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[2] A population-based study of measles, mumps, and rubella vaccination and autism.

Shows: Earlier Danish birth cohort finds no MMR association with autism, other ASD or vaccination age/time since dose.

Does not show: Shares national registry infrastructure with later Danish work; different birth cohorts are not automatically independent assay/error classes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[3] Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association.

Shows: UK regional time/case-series analyses show no introduction-related step or regression/onset clustering after MMR.

Does not show: Symptom timing and diagnostic validation vary; rare effects remain bounded by precision rather than logically impossible.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[4] Autism occurrence by MMR vaccine status among US children with older siblings with and without autism.

Shows: US insured-sibling cohort finds no increased ASD risk after MMR among children with or without an affected older sibling.

Does not show: Familial-risk strata have lower coverage and broad intervals; claims ascertainment and continuous insurance selection remain, and linked correction details unexamined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: JAMA. 2016 Jan 12;315(2):204 (PMID 26757477). Subclaims: SC2, SC3.

[5] Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan atlanta.

Shows: Atlanta cases/controls have similar vaccination by 18 or 24 months; association by 36 months is stronger in the young school-entry group.

Does not show: Later association can reflect early-intervention enrollment requirements; temporal association does not establish exposure before developmental concern.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[6] Association Between First MMR Vaccination Before Age 2 Years and Childhood Autism in a U.S. EHR Cohort of 2.5 Million Children.

Shows: Prespecified age-landmark analyses in 2.56 million US EHR children yield MMR aHR 0.97 and pneumococcal negative-control aHR 1.01.

Does not show: Near-null negative control tests specific shared biases, not every residual confounder; original body not accessed.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[7] MMR vaccination and pervasive developmental disorders: a case-control study.

Shows: UK matched general-practice case-control study finds no increased MMR/PDD association, including pre-media and autism restrictions.

Does not show: Observational exposure/diagnosis recording and vaccine selection remain; no universal zero-risk conclusion.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[8] No effect of MMR withdrawal on the incidence of autism: a total population study.

Shows: Yokohama birth-cohort ASD incidence continues rising after complete MMR withdrawal from 1993.

Does not show: Diagnostic/ascertainment trends can change over time; population withdrawal is stronger against a main cause than against every rare subtype effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[9] MMR and autism: further evidence against a causal association.

Shows: Reanalysis of the earlier UK series still finds no association allowing a longer induction interval.

Does not show: Same source population as PMID 10376617, not an independent cohort or causal line.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[10] Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK.

Shows: Sensitive multiple-region PCR does not detect persistent measles genomes in leukocytes of vaccinated autistic children.

Does not show: Blood sampling cannot exclude every transient event or other tissue; assay null does not alone establish all clinical safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[11] Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine.

Shows: Infant pre/post Pentavac or MMR vaccination shows no significant fecal-calprotectin increase.

Does not show: Short subclinical inflammation endpoint is not a full autism-incidence trial or all gastrointestinal tissue assessment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[12] Elevated levels of measles antibodies in children with autism.

Shows: Autistic children show elevated measles antibody and vaccine-virus immunoblot reactivity in a serologic case-control study.

Does not show: Postdiagnosis immune measurements lack temporal direction, exposure isolation and proof of vaccine-strain persistence or clinical mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[13] Parental report of vaccine receipt in children with autism spectrum disorder: Do rates differ by pattern of ASD onset?

Shows: Parent-reported vaccine receipt is largely equivalent across ASD onset-pattern groups in 2755 children.

Does not show: All participants have ASD and reports are retrospective; onset comparison is not a population incidence or selective exposure experiment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[14] Association between thimerosal-containing vaccine and autism.

Shows: Same-vaccine Danish formulations with or without thimerosal show no increased ASD and no dose trend in 467 450 children.

Does not show: Formulation/calendar assignment remains observational and shares Danish registry failure modes; confidence bounds do not prove absolute zero risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[15] Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism.

Shows: Validated in-person ASD case-control assessment shows no increased risk with prenatal or infant ethylmercury exposure.

Does not show: Medical-record/interview exposure and selection can leave residual confounding; inverse estimates do not prove thimerosal prevents autism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[16] Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.

Shows: UK record cohort finds no autism or general neurodevelopment association, with one positive tic analysis and several inverse associations.

Does not show: Multiplicity, record-based diagnoses and vaccine-selection bias limit interpretation of isolated positive or protective estimates.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[17] Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association.

Shows: Prospective Avon cohort finds one adverse result among 69 comparisons and no convincing overall neurologic/psychological harm pattern.

Does not show: Not all endpoints are autism and many comparisons/selection covariates are tested; isolated significance is not a replicated syndrome.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[18] Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.

Shows: Montreal PDD prevalence rises after thimerosal removal and while MMR uptake declines, without an exposure/dose association.

Does not show: Ecological cohort exposure and changing diagnostic concepts/services prevent trend alone proving no individual effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[19] Continuing increases in autism reported to California's developmental services system: mercury in retrograde.

Shows: California DDS autism prevalence does not decline after removal of more than trace thimerosal from nearly all childhood vaccines.

Does not show: Active-service prevalence is not standardized incidence; diagnostic and access changes complicate withdrawal interpretation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[20] Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.

Shows: Standardized testing of 1047 children finds small mixed positive/negative associations across 42 neuropsychological outcomes.

Does not show: Autism-spectrum disorders were explicitly NOT assessed; this source must not be cited as a direct ASD-incidence null.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[21] Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines.

Shows: Children randomized in infancy to different thimerosal-dose vaccine regimens have few small neuropsychological differences at 10 years.

Does not show: Follow-up participation about 70%, multiple comparisons and other formulation differences limit mediation; the outcome is not an autism-incidence test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[22] Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.

Shows: Two-phase HMO screening detects some tic/language associations that fail independent-site replication; no significant autism increase.

Does not show: Varying ascertainment and many exposure/outcome tests remain; linked erratum lacks a supplied PMID and details unexamined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: Pediatrics. 2004 Jan;113(1):184 (no PMID in the PubMed record). Subclaims: SC1.

[23] Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later.

Shows: Latent-factor reanalysis finds no association for 6 of 7 constructs but a small boys-tic association.

Does not show: Same 1047-child dataset as PMID 17898097; not independent replication, and tics are not autism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[24] Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.

Shows: Birth-cohort VSD mercury estimates associate with several neurodevelopmental diagnostic prevalence outcomes, including autism.

Does not show: Aggregated cohort exposure, calendar/diagnosis changes and reused data undermine individual causal attribution; original authors still recommend routine vaccination.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[25] An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines.

Shows: VAERS report proportions for neurodevelopment fall during thimerosal phaseout in an ecological analysis.

Does not show: Passive adverse-event reports lack population incidence denominators and are sensitive to reporting campaigns, latency and receipt/administration dates.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[26] An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.

Shows: VAERS/education aggregate analyses claim dose-related neurodevelopment associations and compare infant mercury doses to oral methylmercury limits.

Does not show: Ecological/passive-report data and mismatched compound/route guidance do not establish vaccine ethylmercury autism causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[27] Reduced levels of mercury in first baby haircuts of autistic children.

Shows: Autistic-child first haircuts have lower mercury values with maternal-survey exposure differences, interpreted as impaired excretion.

Does not show: Selected postdiagnosis samples and retrospective reporting do not measure native brain burden or prove vaccine exposure caused autism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[28] A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders.

Shows: Small referred ASD series has more Rh-negative mothers than an earlier historical pregnancy-control cohort.

Does not show: Rh status is an imperfect exposure proxy; referral, ancestry, cohort era and immunoglobulin indication confound attribution to thimerosal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[29] Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment.

Shows: Clinic comparisons associate maternal Rh-negativity with neurodevelopmental diagnoses and fewer differences in a small post-2001 group.

Does not show: Potential overlap with earlier clinic work, historical controls, indirect exposure and small later cohort prevent a clean withdrawal experiment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[30] Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study.

Shows: Infant blood/stool measurements estimate rapid ethylmercury blood clearance after thimerosal-containing vaccination.

Does not show: Descriptive pharmacokinetics do not directly assess autism or prove every tissue cleared when blood falls.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[31] Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines.

Shows: Infant vaccination pharmacokinetics estimate a 3.7 day blood half-life and elevated fecal mercury after doses.

Does not show: Population one-compartment modeling, sparse samples and total-Hg measurements are not direct neurodevelopmental outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[32] Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines.

Shows: Late-preterm infants have measured vaccine-associated mercury with estimated 6.3 dayblood half-life and return to baseline by 30 days.

Does not show: Each infant contributes one pre/post sample and population modeling estimates half-life; very-preterm infants, brain clearance and autism are not assessed.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph7. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[33] Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal.

Shows: Infant monkeys show faster blood clearance/lower total brain Hg after thimerosal than methylmercury but a higher inorganic fraction and longer brain than blood retention.

Does not show: Exposure/route and developmental timing differ; pharmacokinetics are not autism outcomes and rapid blood decline is not complete brain clearance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph5, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[34] Neurotoxic effects of postnatal thimerosal are mouse strain dependent.

Shows: Thimerosal challenge produces selected neurobehavioral/pathologic changes in autoimmune-prone SJL mice but not tested C57BL6/BALBc strains.

Does not show: Mapped strain toxicity is not human autism or universal routine-dose harm; peptide/vaccine formulation and species kinetics need transport validation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[35] Lasting neuropathological changes in rat brain after intermittent neonatal administration of thimerosal.

Shows: Repeated neonatal thimerosal dosing causes lasting rat neuropathologic changes in tested dose contexts.

Does not show: Histopathology is not a human ASD diagnosis; authors' dose-equivalence claim does not itself validate pharmacokinetic/developmental transport.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[36] Persistent behavioral impairments and alterations of brain dopamine system after early postnatal administration of thimerosal in rats.

Shows: Neonatal dose/sex-dependent rat behavior and dopamine changes occur, with social changes at the highest dose and spatial-learning null.

Does not show: Behavioral proxies, a wide toxic-dose range and sex dependence do not establish routine human vaccine autism causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[37] Effect of thimerosal on the neurodevelopment of premature rats.

Shows: Premature rat single-dose thimerosal exposure alters learning/memory/apoptosis in selected dose groups.

Does not show: Rat developmental timing, dose units and saline comparator do not isolate actual vaccine-regimen human autism risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[38] Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA.

Shows: Human astrocytes exposed to 0–14.4 micromolar thimerosal show ROS, membrane-potential and mitochondrial-DNA damage.

Does not show: Direct cell exposure demonstrates toxicity at tested concentrations, not infant vaccine tissue kinetics or autism causality; no clinical endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Methods:paragraph0, 1:2. Methods:paragraph10, 2:3. Results:paragraph0, 2:3. Results:paragraph3, 2:3. Results:paragraph12, 2:3. Results:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[39] Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology.

Shows: Infant rhesus vaccine-schedule experiment finds no autism-like social or tested brain pathology differences.

Does not show: Autism-proxy model is not human ASD; linked correction details were not examined and public body retrieval failed in this review.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):E6827 (PMID 26621718). Subclaims: SC1, SC2.

[40] Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: A pilot study.

Shows: Small longitudinal macaque pilot reports amygdala maturation/opioid-imaging differences after a complete vaccine schedule.

Does not show: Pilot imaging biomarkers do not isolate a component or show autism-like functional disease; later larger schedule tests differ.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[41] Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism.

Shows: Validated ASD case-control antigen-load analysis finds no risk increase with cumulative antibody-stimulating vaccine proteins/polysaccharides.

Does not show: Same 256 cases/752 controls as the thimerosal study PMID 20837594; antigen counting is a dose proxy, not every immune-response property.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[42] Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

Shows: DMSA study reports metal excretion/biomarker changes after all participants receive an active screening round, then additional-dose randomization.

Does not show: One-versus-seven rounds lacks a never-treated control; provoked urine reference threshold is arbitrary, reported adverse dropouts occur and biomarkers do not establish vaccine-caused autism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph25, 1:Methods:paragraph26, 1:Methods:paragraph42, 1:Methods:paragraph43, 1:Methods:paragraph47, 1:Methods:paragraph51, 1:Methods:paragraph52, 1:Methods:paragraph53, 1:Methods:paragraph54, 1:Methods:paragraph55. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[43] Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

Shows: Same DMSA study has within-group symptom improvements in both arms without significant between-arm benefit on reported behavior comparisons.

Does not show: All participants already received DMSA, post-dose enrichment and ratings/regressions prevent treatment-versus-untreated or mercury-autism causal inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph5, 2:Results:paragraph14, 2:Results:paragraph20, 2:Results:paragraph26, 2:Results:paragraph28, 2:Results:paragraph30. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[44] Individual and community risks of measles and pertussis associated with personal exemptions to immunization.

Shows: Colorado exemptions predict substantially higher measles/pertussis risk and higher community incidence/outbreak associations.

Does not show: Nonrandom refusal and social/contact clustering remain; actual community associations are distinguished from modeling and pathogen exposure is required.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[45] Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles.

Shows: US exemption cohort finds higher measles risk, with a separate model exploring transmission to nonexempt persons.

Does not show: Community model outputs are not observed rates; age/year/contact and refusal confounding limit standalone causal attribution, linked erratum details unexamined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: JAMA. 2000 May 3;283(17):2241 (no PMID in the PubMed record). Subclaims: SC3, SC4.

[46] Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children.

Shows: Chart-validated Colorado case-control analysis links explicit pertussis refusal to laboratory-confirmed infection.

Does not show: Shared health-plan/contact structure and nonrandom refusal remain; disease protection does not imply vaccination prevents every infection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[47] Parental refusal of varicella vaccination and the associated risk of varicella infection in children.

Shows: Matched Colorado analysis links varicella refusal with more medically attended infection.

Does not show: Small refusal counts and shared health-plan infrastructure limit precision/independence; not a randomized avoidance policy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[48] Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.

Shows: VSD lab-confirmed pertussis cases show increasing risk with more missing/delayed DTaP doses and hospitalizations.

Does not show: Under-vaccination combines delay/refusal/access barriers, with age/time/contact confounding despite matching.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[49] An outbreak of measles in an undervaccinated community.

Shows: Minnesota outbreak has confirmed infection, hospitalizations and an age-eligible safety-concern/refusal subgroup amid falling MMR coverage.

Does not show: Descriptive outbreak has no randomized contact comparator; registry inclusion requires active vaccine records and not all unvaccinated cases were eligible.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph1, 0:METHODS:paragraph2, 0:METHODS:paragraph3, 0:METHODS:paragraph5, 0:METHODS:paragraph6, 0:METHODS:paragraph7. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[50] A Measles Outbreak in an Underimmunized Amish Community in Ohio.

Shows: Imported measles spreads chiefly in low-coverage Amish households, with most cases unvaccinated and limited general-community spread.

Does not show: Contact networks and combined isolation/quarantine/vaccination response prevent attributing every containment effect to one measure.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[51] Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019.

Shows: NYC 2018–19 outbreak records 649 cases with pneumonia, hospitalization/ICU and mostly unvaccinated cases of known status.

Does not show: Importation/contact clustering and combined response measures constrain effect estimation; communities are epidemiologic settings, not intrinsic biological causes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[52] Measles Outbreak - Minnesota April-May 2017.

Shows: Minnesota 2017 laboratory-confirmed outbreak starts in unvaccinated children and expands through low-coverage networks.

Does not show: Early ongoing-outbreak count is not final incidence, and contact exposure/eligibility differ.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[53] Public Health Consequences of a 2013 Measles Outbreak in New York City.

Shows: NYC 2013 measles investigation records largely age-eligible refusal/delay cases and substantial healthcare/public-health exposure burden.

Does not show: Resource accounting/descriptive source cannot alone isolate vaccine effectiveness or population-wide lifetime net health.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[54] A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Shows: Randomized Swedish infant pertussis-component vaccines versus DT-only control reduce confirmed pertussis, with product-specific efficacy and reactogenicity.

Does not show: Controlled antigen prevention is not zero-risk or protection from every pathogen; whole-cell and acellular results differ and linked erratum details unexamined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: N Engl J Med. 1996 May 2;334(18):1207 (no PMID in the PubMed record). Subclaims: SC3, SC4.

[55] Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group.

Shows: Italian randomized pertussis-vaccine follow-up retains clinical protection through 33 months with different product efficacy.

Does not show: Original trial follow-up is one study; control allocation becomes partly unblinded and pertussis protection is time/product specific.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: Vaccine. 1999 Feb 5;17(5):I-II (no PMID in the PubMed record). Subclaims: SC3, SC4.

[56] A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children.

Shows: Randomized varicella-antigen schedules versus MMR-only control provide confirmed-varicella protection through 10 years, with stronger two-dose benefit.

Does not show: Russian subset is part of one international NCT00226499 trial, not an independent efficacy trial; no single cohort establishes all-vaccine safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[57] Risk of anaphylaxis after vaccination in children and adults.

Shows: Chart-adjudicated vaccine-triggered anaphylaxis occurs at 1.31 per million doses across children/adults in VSD.

Does not show: A recognized rare adverse event is not autism or proof every vaccine/recipient has the same risk; doses differ from individuals.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph3, 0:METHODS:paragraph4, 0:METHODS:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[58] MMR vaccine and idiopathic thrombocytopaenic purpura.

Shows: MMR exposure is associated with a short-window excess of childhood ITP with a low estimated attributable risk.

Does not show: Small event counts/broad interval, nonrandom exposure and clinical context remain; no inference to autism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[59] Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.

Shows: First-dose MMRV has about twice the 7–10 day febrile-seizure risk compared with separate MMR plus varicella in 12–23 month-olds.

Does not show: Formulation/age-window adverse effect is not autism or a reason to generalize all vaccination avoidance; partially overlapping VSD follow-ups count as shared components.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[60] Measles-containing vaccines and febrile seizures in children age 4 to 6 years.

Shows: At 4–6 years, MMRV and separate MMR plus varicella show rare seizures without a 7–10 day peak.

Does not show: Age/dose-specific null does not erase the younger first-dose risk and finite precision does not prove zero.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[61] Safety of measles-containing vaccines in 1-year-old children.

Shows: Large VSD analysis confirms seizure/fever and ITP boundaries while other specified events are uncommon or indistinguishable across formulations.

Does not show: Some outcomes have few/zero events; shared VSD population and expandedperiod are not entirely independent safety replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[62] Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders.

Shows: VSD self-controlled analyses find no increased fever/EDresponse difference after measles/pertussis vaccines in diagnosed ASD children aged 4–7 years.

Does not show: Postdiagnosis safety is not autism etiology; rarefebrileseizures and eligible-selection limit generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• research-timeline.json
• vaccine-autism-avoidance.review.md
• vaccine-autism-avoidance.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 62 · load-bearing claims: 67 · verified: 67 · unverified: 0 · contradicted: 0 · schema 5.3